Georges WagnièresGeorges Wagnières received his diploma degree (MSc) in physics from the University of Lausanne, Switzerland, in 1986. He obtained his doctorate in science (PhD) in physics (Biomedical optics) from the Swiss Federal Institute of Technology at Lausanne (EPFL) in 1992 and did a postdoctoral work in the Wellman Laboratories of Photomedicine (Harvard Medical School), Boston, USA, from 1993 to 1994. He also obtained a Master degree in Management of Technology delivered by the Ecole des Hautes Etudes Commerciales (HEC) of Lausanne University and the EPFL in 2001. Georges Wagnières manages a research group active in the fields of: - Detection of early superficial cancers by fluorescence imaging. - Characterization of early superficial cancers by high magnification narrow band imaging. - In vivo and in vitro measurement of the vascular and tissular oxygen concentration by time-resolved luminescence spectroscopy and imaging. - Preclinical and clinical study of new photosensitizers for photodynamic therapy (PDT). - Treatment of neurodegenerative conditions (Alzheimer, Parkinson's diseases) by photobiomodulation. - Preclinical and clinical photodynamic therapy of inflammatory bowel diseases and atheroscerotic plaque. - Improvement of the selective vascular extravasation of chemotherapeutic agents by PDT. - Monitoring the light dosimetry during PDT by fluorescence spectroscopy and imaging. - Monitoring laser treatments of the retina by reflectance imaging. - Light dosimetry and tissue optical spectroscopy. - Radiometry. - Development of light delivery systems for biomedical applications. Georges Wagnières is also co-founder and was chairman of one spin-off companies: - Medlight SA, founded in July 1997, which develops, produces and commercializes light distributors for photodynamic therapy. Georges Wagnières has currently authored more than 235 papers (more than 150 in international journals with review board) and is inventor of 18 patents. He supervised 12 PhD students up to now, and currently teaches biomedical optics and photomedicine in master programs and doctoral schools. In addition, he gives the course entitled "Physique Générale I" to biology first year students registered to the Biology School of the Lausanne's University. MAIN PUBLICATIONS Please visit: https://www.epfl.ch/labs/lifmet/wagnieres/publications/ Stewart ColeProfessor Stewart Cole is an international authority in bacterial molecular-genetics and genomics. He has made outstanding contributions in several fields including: bacterial anaerobic electron transport; genome analysis of retroviruses and papillomaviruses; antibiotic resistance mechanisms; and the molecular microbiology of toxigenic clostridia. His studies on isoniazid and multidrug resistance in Mycobacterium tuberculosis, together with his pioneering work on the pathogenicity, evolution and genomics of the tubercle and leprosy bacilli, have made him an undisputed leader in the field of mycobacterial research. The findings of his research are of direct relevance to public health and disease-control in both the developing world and the industrialised nations. He has published over 250 scientific papers and review articles, and holds many patents.
Bruno LemaitrePersonal Webpage
http://brunolemaitre.ch
Personal Webpage http://brunolemaitre.ch
Teaching & PhD PhD Students Blandine Ribotta, Yao Tian, Désirée Popelka, Prince Kumar Sah, Siqi Wang, Kenan Krakovic, Nathan Alexandre Klotz Past EPFL PhD Students Sveta Chakrabarti, Olivier Binggeli, Jeremy Keith Herren, Juan Camilo Paredes Escobar, Alfred Chng, Maroun Bou Sleiman, Jan Paul Dudzic, Mario Gonzalo Garcia Arraez, Claudia Melcarne, Alice Marra, Bianca Marie Petrignani, Mark Austin Hanson, Alexia Laurie Carboni Didier TronoAfter obtaining an M.D. from the University of Geneva and completing a clinical training in pathology, internal medicine and infectious diseases in Geneva and at Massachusetts General Hospital in Boston, Didier Trono embarked in a scientific career at the Whitehead Institute for Biomedical Research of MIT. In 1990, he joined the faculty of the Salk Institute for Biological Studies to launch a center for AIDS research. He moved back to Europe seven years later, before taking the reins of the newly created EPFL School of Life Sciences, which he directed from 2004 to 2012. He is now actively engaged in the efforts of Switzerland to integrate new technologies in the fields of precision medicine and personalized health.
Elisa OricchioExpertise
Cancer geneticsMouse modelsTherapyStem cellsLymphoma
Teaching & PhD PhD Students Vamsi Krishna Polavarapu, Asli Ece Kasapoglu, Konstantina Georgakopoulou, Eleni Balli Past EPFL PhD Students Maria Christine Donaldson, Elena Battistello, Daniel Pereira Duarte, Frédérica Schyrr, Ruxandra-Andreea Lambuta, Aaron Simone Petruzzella, Jixing Zhong, Justine Epiney Courses Cancer biology I BIO-471 The course covers in detail molecular mechanisms of cancer development with emphasis on cell
Anne-Sophie ChauvinWeb of Science Researcher ID F-4905-2011
Google Scholar page: https://scholar.google.ch/citations?user=O_HhJUEAAAAJ&hl=fr&oi=ao
ORCID number is 0000-0001-9222-3866
Anne-Sophie Chauvin studied chemistry and biology at the university Paris V-René Descartes in France where she did a PhD in organic chemistry, working on mimetic complexes of the active site of Nitrile Hydratase, under the supervision of Prof. Jean-Claude Chottard. On 1999 she moved for 20 months to the University of Geneva, for a post-doctoral stay under the supervision of Prof. Alexandre Alexakis, where she focused on the determination of the absolute configuration of chiral alcohols using Organophosphorous Diamine Derivatizing Agents by 31P and 1H NMR Spectroscopy. On 2000 she joined the group of Prof Jean-Claude G. Bünzli and was appointed part-time lecturer in 2001, assuming teaching and research responsibilities. On 2006, she obtained the habilitation to direct research from the University René Descartes (HDR, Paris V, France) and since october 2007 she is Maître d'Enseignement et de Recherche at the EPFL. In 2010, she joigned the Laboratory for Photonics and Interfaces (LPI), headed by Pr. Michaël Graëtzel. Since the end of 2014, with the arrival of Dr Marinella Mazzanti at EPFL, she is back to lanthanide chemistry, dealing with coordination polymers.
Her research interests concern supramolecular chemistry with the design of ligands which form water soluble complexes with luminescent lanthanides in view of biological applications. She is also interested in the synthesis of ligands and polymers for the extraction of lanthanide ions with high selectivity, and in the development of invisibke inks. She also developed organic dyes for dyes sensitized solar cells DSSC. She is now focusing on coordination polymers with luminescent properties and catalytic activity.
Anne-Sophie Chauvin is involved in the teaching of General and Analytical Chemistry for students enrolled on first year in Pharmacy and Biology (UNIL): ex-cathedra courses (Chimie Générale et analytique I et II, approfondissement en chimie analytique pour pharmaciens) and exercices.
She is in charge of practical sessions for students enroled in chemistry, forensic sciences, pharmacy and biology.
She is elected at the FSB Faculty Council and was member of the EPFL Assembly (AE) for 6 years, until 2018.
She was member of the Management committee of the Cost CM 1006 action entitled Eufen: European F-Element Network.
She is Member of the Swiss Chemical Society (SCS) and Fellow of the Royal Society of Chemistry (FRSC). Solomzi MakohlisoTeaching & PhD Courses Development engineering ENV-470 This course teaches the fundamentals of technologies for development (Development Engineering) to design, pilot, and deploy appropriate, affordable and robust technologies to address sustainable development challenges and especially those related to extreme poverty in Low-income settings. Science, Technology & Vulnerability HUM-287 This course explores how science and technology can address extreme vulnerability caused by
Klaus Benedikt SchönenbergerVision: Scientific research and technology development can be mobilized to help the poorest and most vulnerable in this world. Klaus Schönenberger obtained an MSc in Microengineering (1993), followed by a PhD (1996) from the Swiss Federal Institute of Technology in Lausanne (EPFL). After a post-doc at Lawrence Livermore National Laboratory in California, he spent over 10 years in the medical devices industry in leading positions such as Vice-President of Worldwide R&D in a 100mcompanyandGlobalVice−ResidentofResearchandTechnologyina1bn company. In 2009, as he was working for a medical devices company, he received a shock: he realized that there is a huge imbalance in access to medical technology in industrialized versus low and middle-income countries. After a closer look, he discovered that he imbalance’s main cause is a mismatch between existing technologies and business models, with those needed in low and middle-income countries. He decided to leave industry and, in 2009, he co-founded the EssentialMed Foundation, an innovative non-profit venture. In 2011, realizing that both technology and business models needed a profound rethinking, he joined EPFL where he launched EssentialTech, an initiative inspired by the philosophy of EssentialMed but expanded to a much wider portfolio of "essential" technologies. The university-wide program aims to develop innovative technologies and business models, for the benefit of sustainable development in low and middle-income countries. In this role, he has already launched and overseen a dozen large projects. Major Humanitarian actors such as the ICRC, MSF and Terre des Hommes took notice of the innovative approach proposed, and decided to collaborate in 2015-2016. This has resulted notably in the joint creation between EPFL and ICRC, of the Humanitarian Tech Hub at EPFL. In May 2017, Klaus directed and launched a MOOC(Massive Open Online Course) entitled “Technology Innovation for Sustainable Development” which aims to spread the unique methodology and approach worldwide. As of today, more than 6000 people have enrolled. In 2018 a first spin-off company was created. Award winning Pristem SA will deploy an innovative new digital xray imaging system, specifically designed for low-income contexts. In December 2018, the creation of the EssentialTech centre was announced by EPFL's presidency, and Klaus is now the Centre's director. Another spin-off of the EssentialTech Centre is the company HMCare, launched in 2020, which is deploying a transparent surgical mask. Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Ute KochExpertise
SCIENTIFIC EXPERTISESCurrent Molecular Biology and Cloning, Developmental Biology, Cellular and Molecular Immunology, Lymphocyte Maturation and Lineage Commitment, Thymic Selection, Hematopoietic Stem Cell Biology, Bone Marrow Transplantation, Graft-versus-Host Disease, Skin Transplantation, T Lymphocyte Subset Induction (Th1 - Th2, Cytokine Regulation), Extensive Knowledge in Flow CytometryIT SKILLSMicrosoft-Office: Word, Excel, PowerPoint.File Maker Pro: Database design and management.Flow cytom
Sandrine GerberSandrine Gerber studied chemistry at the "Ecole Nationale Supérieure de Chimie de Paris" in France, where she obtained a diploma of chemical engineer in 1993. The same year she obtained a DEA (Master degree) of organic chemistry at the University Pierre et Marie Curie (Paris VI, France). From 1993 to 1996 she did a PhD in organic chemistry under the supervision of Prof. Jean-Pierre Genêt at the Ecole Nationale Supérieure de Chimie de Paris. In 1996, she moved to University of Lausanne for a post-doctoral stay under the supervision of Prof. Pierre Vogel. In 1998, she was appointed Maître-Assistante at the Institute of Organic Chemistry in the University of Lausanne. In 2003, she obtained the habilitation to direct research from the University Pierre et Marie Curie (Paris VI, France). The same year, she was appointed scientific adjunct at the EPFL and senior scientist (Maître d'Enseignement et de Recherche) in 2006. In December 2014, she was promoted to titular professor. Since September 2007, Sandrine Gerber is deputy to the director of the Institute of Chemical Sciences and Engineering (ISIC). She is also member of the Board of Directors of the Swiss Chemical Society. Since 2007, Sandrine Gerber is part-time lecturer at the university of Fribourg. She was awarded the Prize Eugene Schueller in 1997, the Prize Dufour for prospective organic chemistry in 2005 and the Werner Prize 2010. She also received a special mention in recognition of exceptional quality of pedagogic competencies in the teaching of basic sciences, given by the Direction of the School of Biology and Medicine from the University of Lausanne, in 2013. In October 2018, she will receive the Prize for Excellence in Teaching from the section of Chemistry and Chemical Engineering.
